Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO2 in Relapsed or Refractory Multiple Myeloma
NCT03287804Phase 2Terminated
- Sponsor
- Autolus Therapeutics plc
- Start
- May 2017
- Primary completion
- Sep 2019
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of AUTO2 in multiple myeloma (MM), sponsored by Autolus Therapeutics plc. Primary endpoints: Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period at 28 days, Number of Subjects With a Dose Limiting Toxicity (DLT) at 28 days and 1 more. Started May 2017; status: terminated.
02
Drugs
AUTO2
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03287804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287804.